Related Experiment Video
Updated: Mar 4, 2026
Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
Published on: May 2, 2019
Advances in siRNA delivery in cancer therapy
Aishwarya Singh1, Piyush Trivedi1, Narendra Kumar Jain1
1a School of Pharmaceutical Sciences, Rajiv Gandhi Technical University , Bhopal , Madhya Pradesh , India.
Abstract:
RNA interference (RNAi)-based therapeutic approaches are under vibrant scrutinisation to seek cancer cure. siRNA suppress expression of the carcinogenic genes by targeting the mRNA expression. However, in vivo systemic siRNA therapy is hampered by the barriers such as poor cellular uptake, instability under physiological conditions, off-target effects and possible immunogenicity. To overcome these challenges, systemic siRNA therapy warrants the development of clinically suitable, safe, and effective drug delivery systems. Herein, we review the barriers, potential siRNA drug delivery systems, and application of siRNA in clinical trials for cancer therapy. Further research is required to harness the full potential of siRNA as a cancer therapeutic.
Insights
RNA interference (RNAi) offers a promising avenue for cancer treatment by silencing carcinogenic genes. Overcoming delivery challenges is crucial for effective in vivo systemic RNAi therapy against cancer.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Therapeutics
Background:
- RNA interference (RNAi) is being investigated for cancer cure.
- Small interfering RNA (siRNA) targets and suppresses carcinogenic gene expression at the mRNA level.
- Current in vivo systemic siRNA therapy faces significant hurdles including poor cellular uptake, instability, off-target effects, and immunogenicity.
Purpose of the Study:
- To review the challenges associated with systemic siRNA therapy for cancer.
- To explore potential siRNA drug delivery systems for overcoming these barriers.
- To examine the application of siRNA in ongoing clinical trials for cancer treatment.
Main Methods:
- Literature review of RNAi-based cancer therapeutic approaches.
- Analysis of barriers to in vivo systemic siRNA delivery.
- Evaluation of various siRNA drug delivery systems.
- Review of clinical trial applications of siRNA in oncology.
Main Results:
- Systemic siRNA therapy for cancer is hindered by delivery challenges.
- Development of effective drug delivery systems is essential for clinical success.
- siRNA holds potential for cancer treatment, as evidenced by ongoing clinical trials.
Conclusions:
- Effective drug delivery systems are critical for advancing systemic siRNA cancer therapy.
- Further research is needed to fully realize the therapeutic potential of siRNA in oncology.
- Overcoming delivery barriers will enable the clinical translation of siRNA-based cancer treatments.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...